Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163


Adverse events after stopping clopidogrel in post-acute coronary syndrome patients: Insights from a large integrated healthcare delivery system.

Ho PM, Tsai TT, Wang TY, Shetterly SM, Clarke CL, Go AS, Sedrakyan A, Rumsfeld JS, Peterson ED, Magid DJ.

Circ Cardiovasc Qual Outcomes. 2010 May;3(3):303-8. doi: 10.1161/CIRCOUTCOMES.109.890707. Epub 2010 Mar 30.


Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: implications for transitions of care.

Ho PM, Tsai TT, Maddox TM, Powers JD, Carroll NM, Jackevicius C, Go AS, Margolis KL, DeFor TA, Rumsfeld JS, Magid DJ.

Circ Cardiovasc Qual Outcomes. 2010 May;3(3):261-6. doi: 10.1161/CIRCOUTCOMES.109.902031. Epub 2010 Apr 20.


Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.

Ho PM, Peterson ED, Wang L, Magid DJ, Fihn SD, Larsen GC, Jesse RA, Rumsfeld JS.

JAMA. 2008 Feb 6;299(5):532-9. doi: 10.1001/jama.299.5.532. Erratum in: JAMA. 2008 May 28;299(20):2390.


Discontinuation of long-term clopidogrel therapy is associated with death and myocardial infarction after saphenous vein graft percutaneous coronary intervention.

Sachdeva A, Bavisetty S, Beckham G, Shen AY, Aharonian V, Mansukhani P, Stone GW, Leon M, Moses J, Moore N, Hyett R, Contreras R, Brar SS.

J Am Coll Cardiol. 2012 Dec 11;60(23):2357-63. doi: 10.1016/j.jacc.2012.09.014. Epub 2012 Nov 7.


Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a single integrated health network.

Wiederkehr D, Berenson K, Casciano R, Stern L, Makenbaeva D, Mozaffari E, Lamerato L, Corbelli J.

Curr Med Res Opin. 2009 Sep;25(9):2317-25. doi: 10.1185/03007990903156061.


Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

Ebrahimi R, Dyke C, Mehran R, Manoukian SV, Feit F, Cox DA, Gersh BJ, Ohman EM, White HD, Moses JW, Ware JH, Lincoff AM, Stone GW.

J Am Coll Cardiol. 2009 May 26;53(21):1965-72. doi: 10.1016/j.jacc.2009.03.006.


Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome.

Ho PM, Fihn SD, Wang L, Bryson CL, Lowy E, Maynard C, Magid DJ, Peterson ED, Jesse RL, Rumsfeld JS.

Am Heart J. 2007 Nov;154(5):846-51. Epub 2007 Oct 24.


Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes.

Feldman DN, Fakorede F, Minutello RM, Bergman G, Moussa I, Wong SC.

Am J Cardiol. 2010 Feb 1;105(3):323-32. doi: 10.1016/j.amjcard.2009.09.034. Epub 2009 Dec 22.


Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.

Lewis BS, Mehta SR, Fox KA, Halon DA, Zhao F, Peters RJ, Keltai M, Budaj A, Yusuf S; CURE trial investigators.

Am Heart J. 2005 Dec;150(6):1177-84.


Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy.

Bonello L, De Labriolle A, Lemesle G, Steinberg DH, Roy P, Torguson R, Suddath WO, Satler LF, Kent KM, Pichard AD, Waksman R.

Catheter Cardiovasc Interv. 2009 Jun 1;73(7):866-70. doi: 10.1002/ccd.21935.


Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.

Dosh K, Berger PB, Marso S, van Lente F, Brennan DM, Charnigo R, Topol EJ, Steinhubl S.

Circ Cardiovasc Interv. 2009 Dec;2(6):503-12. doi: 10.1161/CIRCINTERVENTIONS.109.879312. Epub 2009 Nov 17.


Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population.

Wiederkehr D, Ogbonnaya A, Casciano R, Makenbaeva D, Mozaffari E, Corbelli J.

Curr Med Res Opin. 2009 Sep;25(9):2327-34. doi: 10.1185/03007990903156087.


Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.

Murphy SA, Antman EM, Wiviott SD, Weerakkody G, Morocutti G, Huber K, Lopez-Sendon J, McCabe CH, Braunwald E; TRITON-TIMI 38 Investigators.

Eur Heart J. 2008 Oct;29(20):2473-9. doi: 10.1093/eurheartj/ehn362. Epub 2008 Aug 5.


Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions.

Brar SS, Kim J, Brar SK, Zadegan R, Ree M, Liu IL, Mansukhani P, Aharonian V, Hyett R, Shen AY.

J Am Coll Cardiol. 2008 Jun 10;51(23):2220-7. doi: 10.1016/j.jacc.2008.01.063.


Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis.

Berger JS, Frye CB, Harshaw Q, Edwards FH, Steinhubl SR, Becker RC.

J Am Coll Cardiol. 2008 Nov 18;52(21):1693-701. doi: 10.1016/j.jacc.2008.08.031.


Dramatic effect of early clopidogrel administration in reducing mortality and MACE rates in ACS patients. Data from the Swiss registry AMIS-Plus.

Stauffer JC, Goy JJ, Duvoisin N, Radovanovic D, Rickli H, Erne P; AMIS group.

Swiss Med Wkly. 2012 May 9;142:w13573. doi: 10.4414/smw.2012.13573.

Supplemental Content

Support Center